11.08.2017 • NewsDede WillamsLantusInsulin

Sanofi Sues US Merck over Insulin Drug

(c) Pierre Desrosiers/Shutterstock
(c) Pierre Desrosiers/Shutterstock

Sanofi has sued US Merck, alleging infringement of two patents related to an insulin drug. The French drugmaker said the action was triggered by a notification received from Merck in late June.

In the notification, the New Jersey-based company said it had filed a new drug application (NDA) with the US Food and Drug Administration (FDA) for an insulin glargine vial drug product. At the same time it announced it was challenging all of the relevant patents for Sanofi's Lantus and Lantus SoloStar products.

Merck has developed a cheaper follow-on biologic version of Lantus, called Lusduna Nexvue. This is expected to eat into the $6.6 billion sales of the original drug, which accounted for more than a sixth of Sanofi's 2016 total sales.

Eli Lilly also has a Lantus follow-on biologic, Basaglar, which won tentative FDA approval in August 2014. However, the US drugmaker could not launch the drug until December 2016, when it agreed to pay royalties to Sanofi.

Novo Nordisk meanwhile has warned it may have to drop prices of its insulin products in the US next year, as Sanofi will be cutting Lantus prices to thwart biosimilar competition from Lilly as well as Germany’s Boehringer Ingelheim. The Danish pharmaceutical producer said it expects average prices after rebates to be lower than in 2017, as prices of basal insulin are falling.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.